Literature DB >> 18704401

Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up.

Shu-Hang Ng1, Sheng-Chieh Chan, Tzu-Chen Yen, Joseph Tung-Chieh Chang, Chun-Ta Liao, Sheung-Fat Ko, Feng-Yuan Liu, Shu-Chyn Chin, Kang-Hsing Fan, Cheng-Lung Hsu.   

Abstract

PURPOSE: We prospectively compared PET/CT and conventional imaging for initial staging of nasopharyngeal carcinoma (NPC).
METHODS: A total of 111 patients with histologically proven NPC were investigated with PET/CT and conventional imaging (head-and-neck MRI, chest X-ray, abdominal ultrasound, and bone scan) before treatment. The respective findings were reviewed independently and then compared with each other.
RESULTS: With regard to T staging, PET/CT showed a discrepancy with head-and-neck MRI in 36 (32.4%) of the study subjects. With regard to N staging, PET/CT showed a discrepancy with head-and-neck MRI in 15 (13.5%) patients. Among the discordant cases, MRI was superior in demonstrating tumor involvement in the parapharyngeal space, skull base, intracranial area, sphenoid sinus, and retropharyngeal nodes while PET/CT was superior in demonstrating neck nodal metastasis. PET/CT disclosed 13 of 16 patients with distant malignancy compared with four patients disclosed by conventional imaging work-up. The false-positive rate of PET/CT was 18.8%. PET/CT correctly modified M staging in eight patients (7.2%) and disclosed a second primary lung malignancy in one patient (0.9%).
CONCLUSION: In NPC patients, MRI appears to be superior to PET/CT for the assessment of locoregional invasion and retropharyngeal nodal metastasis. PET/CT is more accurate than MRI for determining cervical nodal metastasis and should be the better reference for the neck status. PET/CT has an acceptable diagnostic yield and a low false-positive rate for the detection of distant malignancy and can replace conventional work-up to this aim. PET/CT and head-and-neck MRI are suggested for the initial staging of NPC patients.

Entities:  

Mesh:

Year:  2008        PMID: 18704401     DOI: 10.1007/s00259-008-0918-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  52 in total

1.  [Comparison between PET/CT and MRI in diagnosing lymph node metastasis and N staging of nasopharyngeal carcinoma].

Authors:  Gu-yi Zhang; Wei-han Hu; Li-zhi Liu; Hu-bing Wu; Yuan-hong Gao; Li Li; Yi Pan; Quan-shi Wang
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2006-05

2.  Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer.

Authors:  Arnold C Paulino; Mary Koshy; Rebecca Howell; David Schuster; Lawrence W Davis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-04-01       Impact factor: 7.038

3.  18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.

Authors:  Shu-Hang Ng; Tzu-Chen Yen; Chun-Ta Liao; Joseph Tung-Chieh Chang; Sheng-Chieh Chan; Sheung-Fat Ko; Hung-Ming Wang; Ho-Fai Wong
Journal:  J Nucl Med       Date:  2005-07       Impact factor: 10.057

4.  Retropharyngeal lymphadenopathy in nasopharyngeal carcinoma.

Authors:  W W Lam; Y L Chan; S F Leung; C Metreweli
Journal:  Head Neck       Date:  1997-05       Impact factor: 3.147

5.  Defining a radiotherapy target with positron emission tomography.

Authors:  Quinten C Black; Inga S Grills; Larry L Kestin; Ching-Yee O Wong; John W Wong; Alvaro A Martinez; Di Yan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-11-15       Impact factor: 7.038

6.  The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx.

Authors:  Tzu-Chen Yen; Joseph Tung-Chieh Chang; Shu-Hang Ng; Yu-Chen Chang; Sheng-Chieh Chan; Kun-Ju Lin; Wuu-Jyh Lin; Ying-Kai Fu; Chen-Yu Lin
Journal:  J Nucl Med       Date:  2005-03       Impact factor: 10.057

7.  Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging.

Authors:  Christopher Scarfone; William C Lavely; Anthony J Cmelak; Dominique Delbeke; William H Martin; Dean Billheimer; Dennis E Hallahan
Journal:  J Nucl Med       Date:  2004-04       Impact factor: 10.057

8.  Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion.

Authors:  Heiko Schöder; Henry W D Yeung; Mithat Gonen; Dennis Kraus; Steven M Larson
Journal:  Radiology       Date:  2004-02-27       Impact factor: 11.105

9.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.

Authors:  Didier Lardinois; Walter Weder; Thomas F Hany; Ehab M Kamel; Stephan Korom; Burkhardt Seifert; Gustav K von Schulthess; Hans C Steinert
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

10.  Fluorodeoxyglucose-positron emission tomography/computed tomography imaging in patients with carcinoma of the larynx: diagnostic accuracy and impact on clinical management.

Authors:  Arie Gordin; Marcello Daitzchman; Ilana Doweck; Nikolay Yefremov; Avishay Golz; Zohar Keidar; Rachel Bar-Shalom; Abraham Kuten; Ora Israel
Journal:  Laryngoscope       Date:  2006-02       Impact factor: 3.325

View more
  42 in total

1.  Automatic detection and classification of nasopharyngeal carcinoma on PET/CT with support vector machine.

Authors:  Bangxian Wu; Pek-Lan Khong; Tao Chan
Journal:  Int J Comput Assist Radiol Surg       Date:  2012-01-04       Impact factor: 2.924

2.  Magnetic resonance imaging staging of nasopharyngeal carcinoma in the head and neck.

Authors:  Ann Dorothy King; Kunwar Suryaveer Singh Bhatia
Journal:  World J Radiol       Date:  2010-05-28

3.  PET/CT for staging and follow-up of pediatric nasopharyngeal carcinoma.

Authors:  Daniel K L Cheuk; Noah D Sabin; Moinul Hossain; Amy Wozniak; Mihir Naik; Carlos Rodriguez-Galindo; Matthew J Krasin; Barry L Shulkin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-25       Impact factor: 9.236

4.  MRI-detected skull-base invasion: prognostic value and therapeutic implication in intensity-modulated radiotherapy treatment for nasopharyngeal carcinoma.

Authors:  Yi-Kan Cheng; Li-Zhi Liu; Ning Jiang; Dan Yue; Ling-Long Tang; Fan Zhang; Li Lin; Xu Liu; Lei Chen; Jun Ma
Journal:  Strahlenther Onkol       Date:  2014-04-25       Impact factor: 3.621

Review 5.  The evolution of nasopharyngeal carcinoma staging.

Authors:  Rui Guo; Yan-Ping Mao; Ling-Long Tang; Lei Chen; Ying Sun; Jun Ma
Journal:  Br J Radiol       Date:  2019-07-12       Impact factor: 3.039

6.  Comparison of MRI, CT and 18F-FDG PET/CT in the diagnosis of local and metastatic of nasopharyngeal carcinomas: an updated meta analysis of clinical studies.

Authors:  Wang-Sheng Chen; Jian-Jun Li; Lan Hong; Zeng-Bao Xing; Fen Wang; Chang-Qing Li
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

7.  18F-Fluorodeoxyglucose-PET/CT in locally advanced head and neck cancer can influence the stage migration and nodal radiation treatment volumes.

Authors:  Rosario Mazzola; Pierpaolo Alongi; Francesco Ricchetti; Alba Fiorentino; Sergio Fersino; Niccolò Giaj-Levra; Matteo Salgarello; Filippo Alongi
Journal:  Radiol Med       Date:  2017-08-28       Impact factor: 3.469

Review 8.  Meta-analysis of diagnostic value of 18F-FDG PET or PET/CT for detecting lymph node and distant metastases in patients with nasopharyngeal carcinoma.

Authors:  G Shen; W Zhang; Z Jia; J Li; Q Wang; H Deng
Journal:  Br J Radiol       Date:  2014-10-28       Impact factor: 3.039

9.  Robustness of Radiomic Features in [11C]Choline and [18F]FDG PET/CT Imaging of Nasopharyngeal Carcinoma: Impact of Segmentation and Discretization.

Authors:  Lijun Lu; Wenbing Lv; Jun Jiang; Jianhua Ma; Qianjin Feng; Arman Rahmim; Wufan Chen
Journal:  Mol Imaging Biol       Date:  2016-12       Impact factor: 3.488

10.  Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer.

Authors:  Akram Al-Ibraheem; Andreas Buck; Bernd Joachim Krause; Klemens Scheidhauer; Markus Schwaiger
Journal:  J Oncol       Date:  2009-08-20       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.